Amplification of the HER2 (also known as ERBB2) oncogene and overexpression of the HER2 protein occurs in approximately 17%-20% of patients with GCs and is more common in intestinal-type GC and cancers located in the proximal stomach or at the gastroesophageal junction (GEJ).5 This evidence concerns the gene ERBB2 and gastric cancer.